Radiation boosts failing breast cancer drugs in new trial

NCT ID NCT06925984

Recruiting now Disease control Sponsor: Jules Bordet Institute Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 18 times

Summary

This study tests whether precisely targeted radiation (SBRT) can extend the usefulness of current hormone therapy or CDK4/6 inhibitors in women with ER+/HER2- metastatic breast cancer that has started to progress in just 1-3 spots. Participants continue their existing medication while getting radiation on the growing tumors. The goal is to delay switching to a new treatment, potentially keeping a well-tolerated therapy effective longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AZ Groeninge
RECRUITING

Kortrijk, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••
AZ Sint-Maarten
RECRUITING

Mechelen, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••
CHU UCL Namur - Site Saint Elisabeth
RECRUITING

Namur, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••
Jules Bordet Institute
RECRUITING

Brussels, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••
UZ Gent
RECRUITING

Ghent, Belgium

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

OLIGOPROGRESSIVE METASTATIC DISEASE